Clinical trial
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of…
NCT00134563 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00134563 |
|---|---|
| Title | Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses |
| Acronym | TEMSO |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Teriflunomide, Placebo (for teriflunomide) |
| Enrollment | 1,088 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Aug 25, 2005 |
| Last update posted | Jan 4, 2013 |
| Countries | Austria, Canada, Chile, Czechia, Denmark, Estonia, Finland, France, Germany, Italy, Netherlands, Norway and 9 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: